Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00395057 · ClinicalTrials.gov registry record · Phase 2
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
A Phase 2 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT00395057 is a Phase 2 study that was terminated before completion, run by Allergan. The registered enrollment target is 138 participants.
The verdict
NCT00395057, a Phase 2 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
Interventions
- DRUG AGN 211745
- DRUG Ranibizumab 500µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00395057
The ClinicalTrials.gov registry entry for NCT00395057 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AGN 211745 is the first listed.
NCT00395057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00395057 about?
NCT00395057 is a clinical study titled "A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration". This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
What is the current status of trial NCT00395057?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2007-01. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00395057?
The interventions under investigation include: AGN 211745 (DRUG), Ranibizumab 500µg (DRUG).
Who is sponsoring clinical trial NCT00395057?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.